2 active not recruiting, 1 completed, 1 not yet recruiting, 1 terminated. 3 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Leber Hereditary Optic Neuropathy (LHON): new trials by email Literature Review of Leber Hereditary Optic Neuropathy (LHON) trials Research Report on Leber Hereditary Optic Neuropathy (LHON)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pilot Study of the Efficacy of Nicotinamide (Vitamin B3) in Leber's Hereditary Optic Neuropathy Nicotinamide treatment - Leber Hereditary Optic Neuropathy (LHON), Leber's Hereditary Optic Neuropathy (LHON) | Phase 1 | Not yet recruiting | University Hospital, Angers | 13 | 2026-04-01 | 2025-12-18 |
| A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation rAAV2-ND4, Sham (No Treatment) - Leber Hereditary Optic Neuropathy (LHON) | Phase 3 | Active not recruiting | Wuhan Neurophth Biotechnology Limited Company | 95 | 2024-09-19 | 2026-02-12 |
| Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 Mutations NFS-02 Injection - Leber Hereditary Optic Neuropathy (LHON) | Phase 1 / Phase 2 | Terminated | Neurophth Therapeutics Inc | 11 | 2023-08-15 | 2024-09-20 |
| Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations NR082 Injection, Injection needle - Leber Hereditary Optic Neuropathy (LHON) | Phase 1 / Phase 2 | Active not recruiting | Neurophth Therapeutics Inc | 12 | 2023-05-22 | 2024-09-04 |
| Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey Leber Hereditary Optic Neuropathy (LHON) | Completed | Santhera Pharmaceuticals | 306 | 2013-08-01 | 2014-05-15 |
Optic Atrophy, Hereditary, Leber (5) · Mitochondrial Diseases (1) · Optic Nerve Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Cranial Nerve Diseases (5) · Eye Diseases (5) · Eye Diseases, Hereditary (5) · Genetic Diseases, Inborn (5) · Heredodegenerative Disorders, Nervous System (5) · Metabolic Diseases (5) · Nervous System Diseases (5) · Neurodegenerative Diseases (5) · Nutritional and Metabolic Diseases (5) · Optic Atrophies, Hereditary (5) · Optic Atrophy (5) · Mitochondrial Diseases (4) · Optic Nerve Diseases (4)
Needles (1) · Syringes (1) · salicylhydroxamic acid (1)
Neurophth Therapeutics Inc (2) · Santhera Pharmaceuticals (1) · University Hospital, Angers (1) · Wuhan Neurophth Biotechnology Limited Company (1)
China (2) · France (2) · United States (2) · Belgium (1) · Denmark (1) · Italy (1) · Slovenia (1)
2025 (1)